On Thursday, Johnson & Johnson submitted its COVID-19 vaccine for emergency use in the United States. If greenlit by the Food and Drug Administration, it could be the nation’s third COVID vaccine producer, joining Pfizer and Moderna.
Between the three manufacturers, there could be enough COVID vaccines to inoculate the whole adult U.S. population by summer, according to Johnson & Johnson board member Mark McClellan, MD.
Last week, Johnson & Johnson said in a press release that its single dose vaccine is 66% effective overall at preventing moderate to severe COVID-19, 28 days after vaccination. (The FDA’s cutoff point for a COVID vaccine’s effectiveness
→ Continue reading at Yahoo Health